Company Number: 12867553

Analysis Date: 2025-07-20 15:47 UTC

Financial Health Assessment of Urgo2 Ltd as of 30 September 2024

---

1. Financial Health Score: C+

Explanation:
Urgo2 Ltd demonstrates improving financial health compared to previous years, with positive net assets and working capital, but still faces notable financial strain from significant long-term liabilities. The company exhibits signs of recovery from earlier distress but needs to address its leverage and liquidity issues more robustly to secure a healthier financial position.

---

2. Key Vital Signs

Metric	2024 Value (£)	Interpretation
Net Assets (Shareholder Funds)	155,305	Positive and growing net assets indicate the company has moved from negative equity to positive territory, a sign of financial recovery.
Working Capital (Net Current Assets)	85,463	Healthy positive working capital signals the company can cover short-term obligations comfortably, improving liquidity stance.
Current Ratio	1.39	Current Assets (£307k) / Current Liabilities (£221k). Above 1 indicates reasonable short-term liquidity.
Leverage (Long-term Debt)	£514,238	Substantial long-term obligations compared to net assets; signals financial strain and potential over-reliance on debt financing.
Fixed Assets	£584,080	Significant investment in long-term assets, which may be illiquid but represent operational capacity.
Cash at Bank	£53,812	Moderate cash reserves relative to current liabilities, adequate but could be improved for buffer.
Profit and Loss Reserve	£155,304	Accumulated profits indicate operational success over time, contributing to equity growth.
Employee Count	15	Small workforce consistent with a small to medium enterprise scale, implying manageable payroll obligations.

---

3. Diagnosis

Urgo2 Ltd has undergone a financial transformation over the past four years. Initially, the company was in a state of distress, reflected by negative net assets and negative working capital in 2020 and 2021. These were clear "symptoms" of financial illness — inability to meet short-term liabilities and erosion of shareholder equity.

The recent accounts show a "healthier pulse": net assets have turned positive and almost doubled from £80k in 2023 to £155k in 2024. Working capital has improved significantly from marginally positive (£9,646) to a more comfortable £85,463, suggesting improved liquidity and operational cash flow management.

However, the company's "long-term debt burden" remains a critical concern. With over half a million pounds in obligations under finance leases and hire purchase contracts, this high leverage imposes a chronic strain on financial flexibility. This debt load could be likened to a "chronic illness" that requires continuous management to avoid relapse into financial distress.

Operationally, the company seems stable, maintaining a consistent employee base and investing steadily in fixed assets, both tangible and intangible. The amortisation and depreciation charges are moderate, indicating ongoing asset utilisation.

In summary, Urgo2 Ltd is recovering from past financial distress, showing signs of a strengthening balance sheet and improved liquidity. However, the significant long-term liabilities pose a risk that requires ongoing attention.

---

4. Recommendations

1. Debt Management Strategy:

• Engage with lenders to explore refinancing options to reduce interest costs or extend maturities.
• Consider negotiating terms on finance leases to ease cash flow pressures.
• Develop a clear repayment plan to gradually reduce debt.

2. Cash Flow Monitoring and Improvement:

• Maintain healthy working capital by improving debtor collection cycles and controlling inventory levels.
• Increase cash reserves to build a buffer against unexpected expenses or downturns.

3. Operational Efficiency:

• Review cost structure to identify potential savings without compromising growth.
• Invest in sales and marketing to increase turnover, improving profit margins and cash generation.

4. Equity Considerations:

• Explore opportunities for equity injection from existing or new shareholders to strengthen the capital base.
• Transparent communication with shareholders and stakeholders about financial plans and progress.

5. Financial Reporting and Governance:

• Continue timely filing of accounts and confirmation statements to maintain good standing.
• Consider periodic external financial reviews or audits to enhance credibility.

---

Medical Analogy Summary

Urgo2 Ltd has moved from a "critical condition" with negative equity and liquidity strains to a "stable patient" with positive net assets and working capital. However, it carries a "chronic debt condition" that acts like a persistent ailment—manageable but requiring ongoing treatment to prevent relapse. With prudent financial management and strategic interventions, the company can advance towards full financial wellness.

---